ViAqua Therapeutics develops an orally administered RNA-particle platform designed to prevent diseases in aquaculture species. Its first product is a feed supplement to enhance shrimp resistance to viral infections, initially targeting White Spot Virus (WSSV). The company says the solution will provide production stability for farmers and enable increased production per farm without raising disease risk. ViAqua intends to use the new funding to bring its first product to market and to invest in R&D for future products. The company plans to begin production in India at the beginning of 2024 and has a joint development and marketing agreement with Skretting, a Nutreco company. The company is led by CEO Shai Ufaz and is based in Haifa, Israel. ViAqua Therapeutics develops an orally administered RNA-particle platform using RNA and an encapsulated delivery method to promote shrimp and aquatic animal health, including protection against viral challenges. The company is commercializing its first shrimp health product and plans to develop additional products for aquatic animal health and nutrition. ViAqua intends to use the recent funding to support that commercialization and further product development. The company is led by CEO Shai Ufaz and is based in Misgav, Israel. The platform targets prevalent and devastating viral diseases in shrimp through orally delivered RNA particles.

Total raised

$12M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2023